Human myeloid leukemia cells metabolize 25-hydroxyvitamin D3 in vitro.
Human promyelocytic leukemia cells (HL-60) converted 25-hydroxyvitamin D3 to two more polar metabolites during in vitro incubations. A two-step high pressure liquid chromatography system revealed two unique elution positions of those leukemic cell-derived metabolites that exactly co-migrated with the elution positions of 5(Z)-19-nor-10-oxo-25-hydroxyvitamin D3 and 5(E)-19-nor-10-oxo-25-hydroxyvitamin D3, respectively. These unique metabolites did not bind specifically to a protein receptor for 1,25-dihydroxyvitamin D3.
Okabe
T
T
Ishizuka
S
S
Fujisawa
M
M
Watanabe
J
J
Takaku
F
F
D000818:Animals; D001711:Biotransformation; D002112:Calcifediol / Q000378:metabolism*; D002460:Cell Line; D002499:Centrifugation, Density Gradient; D002645:Chickens; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D066298:In Vitro Techniques; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D018167:Receptors, Calcitriol; D011987:Receptors, Steroid / Q000378:metabolism
D018167:Receptors, Calcitriol; D011987:Receptors, Steroid; D002112:Calcifediol